AXIN2 and cancer: Furthermore, we identified notable correlation between AXIN2 1365 C/T variant and cancer risk (allele contrast: OR = 0.71, 95% CI 0.61–0.98, Pheterogeneity = 0.873, P = 0.038; heterozygote comparison: OR = 0.63, 95% CI 0.44–0.91, Pheterogeneity = 0.668, P = 0.014; dominant model: OR = 0.66, 95% CI 0.47–0.94, Pheterogeneity = 0.775, P = 0.021).